Tesamorelin and Ipamorelin as a Peptide Blend

By GetOPT Review Team · October 23, 2026 ·Part of our Peptide Therapy Guide

Tesamorelin is a growth hormone-releasing hormone analog, while ipamorelin is a ghrelin-receptor agonist that stimulates growth hormone release through a different pathway. The reason for combining them is biologically plausible, but no human trial of the tesamorelin ipamorelin combination was found. Tesamorelin has clinical evidence for one specific population. Ipamorelin has far less human evidence, and the combination has no proven effect on fat loss, muscle growth, sleep, or recovery. Your physician can read your IGF-1, glucose, and history to decide whether either peptide fits you at all.

The Two Peptides in the Combination

Growth hormone (GH) is released by the pituitary gland. It also raises insulin-like growth factor 1 (IGF-1), a growth factor your physician can measure in your blood.

Tesamorelin and ipamorelin act on separate parts of this system.

Peptide	Mechanism	Regulatory Status	Human Evidence
Tesamorelin	Mimics growth hormone-releasing hormone (GHRH), which signals the pituitary to release GH	FDA-approved as EGRIFTA for reducing excess abdominal fat in adults with HIV-associated lipodystrophy	Randomized trials support its approved indication
Ipamorelin	Activates the ghrelin receptor, also called the growth hormone secretagogue receptor	No FDA-approved indication	Limited clinical development, including an unsuccessful phase 2 trial for postoperative ileus
Tesamorelin and ipamorelin blend	Attempts to stimulate GH through two pathways	No approved combination product	No human trial of the combination was found

A blend does not inherit the evidence for its individual ingredients. Tesamorelin’s trial results cannot establish that adding ipamorelin improves those results.

A fixed blend cannot account for different labs and goals. A physician-led decision uses your labs and goals to determine whether a peptide fits at all, then uses follow-up results to adjust the plan.

For a wider look at how peptides are evaluated and prescribed, see peptide therapy.

Tesamorelin Evidence in HIV-Associated Lipodystrophy

Tesamorelin is a synthetic GHRH analog sold under the EGRIFTA name. The U.S. Food and Drug Administration (FDA) label approves it for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.¹

That indication is narrow. The label states that tesamorelin is not indicated for weight management and has a weight-neutral effect.¹ It does not approve tesamorelin for general belly-fat reduction, athletic performance, or use in a peptide blend.

In a randomized trial of 412 people with HIV and excess abdominal fat, visceral adipose tissue decreased by 15.2% in the tesamorelin group and increased by 5.0% with placebo after 26 weeks.² Visceral adipose tissue is fat stored around the internal organs.

A pooled analysis of 806 patients reported a 15.4% treatment effect on visceral fat at 26 weeks. It found no significant change in abdominal subcutaneous fat, which is the fat directly beneath the skin.³ The reduction in visceral fat was maintained through 52 weeks among participants who continued treatment.³

These participants had HIV, were receiving antiretroviral therapy, and had excess abdominal fat. If you do not fit that population, the trials cannot predict your result. A belly-fat measurement gives your physician one data point. IGF-1, glucose, and body composition measured over time provide a broader pattern for a treatment decision. The full evidence review is available on the tesamorelin peptide page.

Ipamorelin Evidence and Research History

Ipamorelin is a synthetic pentapeptide that activates the ghrelin receptor and stimulates GH release. Early experiments found selective GH release without comparable increases in adrenocorticotropic hormone or cortisol, but those experiments used rat cells, rats, and pigs.⁴

Animal findings do not establish a body-composition benefit in people. A later review reported that ipamorelin increased fat-pad weight, body-fat percentage, and early weight gain in mice. The review concluded that further human studies were needed.⁵

Ipamorelin’s main published human efficacy trial studied intravenous treatment for postoperative ileus after bowel surgery. Among 114 analyzed patients, ipamorelin showed no significant difference from placebo in the key and secondary efficacy analyses.⁶ That hospital trial did not examine subcutaneous use, healthy adults, fat loss, or long-term safety.

If you are considering ipamorelin for weight loss or body composition, the human evidence does not establish that result. Your physician can measure your body composition, IGF-1, and glucose to find what is driving the change you want before any peptide is considered.

Why Tesamorelin and Ipamorelin Are Paired

The tesamorelin and ipamorelin blend is based on two-pathway stimulation of GH release. Tesamorelin acts through the GHRH receptor, while ipamorelin acts through the ghrelin receptor.^1,4

A small study in 18 healthy men found that native GHRH and growth hormone-releasing peptide 6 (GHRP-6) produced a greater acute GH response together than either compound alone.⁷ This provides a mechanism for pairing a GHRH analog with a growth hormone-releasing peptide.

The study did not test tesamorelin or ipamorelin. It used single intravenous exposures and measured short-term GH release over several hours.⁷ It did not measure visceral fat, muscle mass, sleep, recovery, or long-term safety.

PubMed and ClinicalTrials.gov list no human trial of tesamorelin combined with ipamorelin. A 2026 review also described peptide stacking claims as having limited controlled clinical support.⁸

The pairing therefore rests on mechanism. It does not have human outcome data. A peptide stack can be presented as a shortcut for belly fat or recovery. Your labs, history, and goals determine whether GH-axis therapy belongs in the discussion. If a clinic promises specific tesamorelin ipamorelin results, ask for the human trial supporting that exact combination.

Side Effects and Clinical Monitoring

Tesamorelin has defined safety information because it has an FDA-approved label and randomized clinical trials. Common adverse reactions include joint pain, muscle pain, peripheral edema, limb pain, and injection-site redness or itching.¹

Tesamorelin can raise IGF-1 and may cause fluid retention or glucose intolerance. In the clinical trials reported on the FDA label, an HbA1c level of 6.5% or higher developed in 5% of tesamorelin-treated participants and 1% of placebo-treated participants by week 26.¹ Hypersensitivity reactions occurred in 4% of participants receiving tesamorelin.¹

If you have an active malignancy or a disrupted hypothalamic-pituitary axis, the FDA label rules tesamorelin out. Pregnancy and known hypersensitivity are additional contraindications.¹

Ipamorelin does not have an FDA-approved label that defines adverse-effect rates for the injectable uses promoted by peptide clinics. The FDA cites concerns about immune reactions, peptide aggregation, impurities, and unnatural amino acids in compounded ipamorelin acetate.⁹ The agency also cites serious adverse events, including a death associated with intravenous administration, while stating that safety information for certain other injectable routes is insufficient.⁹

Your physician should review your medical history, medications, glucose markers, and cancer risk before considering GH-axis therapy. During treatment, IGF-1 and glucose help show how your body is responding. Symptoms and lab trends belong in the same review.

Regulatory Status of the Combination

Tesamorelin is available as the FDA-approved EGRIFTA product for its HIV-associated lipodystrophy indication.¹ Two EGRIFTA formulations exist, and the label states that they are not interchangeable.¹

Ipamorelin has no FDA-approved indication. As of the FDA page updated April 22, 2026, ipamorelin acetate appears in category 2 under the 503B interim compounding policy because it may present safety risks.⁹ The FDA page does not mention tesamorelin’s compounding status.

There is no approved tesamorelin and ipamorelin blend. If cost is part of your decision, compare the medication, lab, and clinical-monitoring charges separately. The peptide therapy cost guide explains those line items.

The Opt Take on Tesamorelin and Ipamorelin

An Opt Health physician decides whether any GH-axis peptide fits your labs, medical history, medications, and goals before a prescription is considered. The physician prescribes only what is appropriate and reviews how your body responds.

The process starts with a panel of 55+ biomarkers and a 1:1 physician review. IGF-1 and glucose are read together with symptoms, medical history, and body-composition goals. One belly-fat measurement or one lab result cannot define the plan. The pattern guides the decision.

Labs and a physician consultation repeat every 3 to 4 months. Each review tracks IGF-1 and glucose and gives the physician a chance to continue, change, or stop the plan based on the results. This loop keeps a fixed peptide blend from becoming the default for every body-composition goal.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

What is the recommended dosing for CJC-1295 ipamorelin?

Ipamorelin has no FDA-approved label, so there is no approved dose for a CJC-1295 and ipamorelin combination. Dosing for any compounded peptide is set by the prescribing physician after reviewing your health history and labs. See the CJC-1295 ipamorelin guide for the evidence and regulatory concerns.

What are the differences between ipamorelin and sermorelin?

Ipamorelin activates the ghrelin receptor, while sermorelin is a GHRH analog that acts through the GHRH receptor.⁵ Both raise GH through different pathways, and the 2020 review that describes both mechanisms does not compare them head to head in people. See sermorelin vs ipamorelin for the focused comparison.

How often should I inject tesamorelin?

The FDA label sets the tesamorelin schedule for its approved HIV-associated lipodystrophy indication, and your prescriber determines the schedule that applies to your prescription. The two EGRIFTA formulations have different labeled requirements and cannot be substituted for each other.¹

Is ipamorelin effective for weight loss?

Human studies have not established ipamorelin as an effective weight-loss treatment. The body-composition findings cited in one review came from mice and included increased fat and early weight gain, so they cannot support a human fat-loss claim.⁵

What are the downsides of ipamorelin?

Ipamorelin has no FDA-approved indication and little human efficacy evidence. Its phase 2 postoperative ileus trial found no efficacy advantage over placebo, while the FDA has identified concerns involving immune reactions, impurities, and uncertain safety through injectable routes.^6,9 There are no established human incidence rates for side effects from the subcutaneous uses promoted for body composition.

What is the best peptide for belly fat?

No peptide has been established as the best treatment for belly fat. Tesamorelin reduced visceral fat in adults with HIV-associated lipodystrophy, but its label says it is not indicated for weight management.^1-3 The pooled trials also found no significant change in abdominal subcutaneous fat.³ Your physician should first identify whether the concern is visceral fat, subcutaneous fat, overall weight, or a metabolic condition.

An Opt Health membership starts with a panel of 55+ biomarkers and a 1:1 physician review. Your physician can assess whether GH-axis therapy fits your history and goals, then reassess the plan every 3 to 4 months.

References

U.S. Food and Drug Administration. EGRIFTA WR (tesamorelin) for injection, for subcutaneous use: full prescribing information. Revised March 2025. Accessed October 23, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. https://pubmed.ncbi.nlm.nih.gov/18057338/
Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. https://pubmed.ncbi.nlm.nih.gov/20554713/
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. https://pubmed.ncbi.nlm.nih.gov/9849822/
Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. https://pubmed.ncbi.nlm.nih.gov/32257855/
Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. https://pubmed.ncbi.nlm.nih.gov/25331030/
Bowers CY, et al. Growth hormone-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-982. https://pubmed.ncbi.nlm.nih.gov/2108187/
Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. https://pubmed.ncbi.nlm.nih.gov/42395176/
U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Updated April 22, 2026. Accessed October 23, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks